Cardiac Resynchronization Therapy Defibrillator Treatment in a Child with Heart Failure and Ventricular Arrhythmia.
Cardiac Resynchronization Therapy Defibrillator Treatment in a Child with Heart Failure and Ventricular Arrhythmia. Korean J Thorac Cardiovasc Surg. 2016 Aug;49(4):292-4 Authors: Kim HJ, Cho S, Kim WH Abstract Cardiac resynchronization therapy (CRT) is a new treatment for refractory heart failure. However, most patients with heart failure treated with CRT are adults, middle-aged or older with idiopathic or ischemic dilated cardiomyopathy. We treated a 12-year-old boy, who was transferred after cardiac arrest, with dilated cardiomyopathy, left bundle-branch block, and ventricular tachycardia. We performed cardiac resynchronization therapy with a defibrillator (CRT-D). After CRT-D, left ventricular ejection fraction improved from 22% to 44% assessed by echocardiogram 1 year postoperatively. On electrocardiogram, QRS duration was shortened from 206 to 144 ms. The patient's clinical symptoms also improved. For pediatric patients with refractory heart failure and ventricular arrhythmia, CRT-D could be indicated as an effective therapeutic option. PMID: 27525239 [PubMed]
Conclusions: Approximately, one-fourth of patients developed hyperkalaemia during follow-up which was associated with a lower MRA dose during follow-up. Discontinuation of MRA, but not hyperkalaemia itself, was associated with an increased risk of all-cause mortality and heart failure admission in HFrEF patients. PMID: 32264757 [PubMed - as supplied by publisher]
Conclusion: ART may reduce the risk of NCIs in HIV-infected patients in general. Further research to investigate NCIs on specific antiretroviral regimens and comorbidities may provide insights regarding the long-term clinical care of these patients.
Conclusions/interpretationOur study provides the first evidence thatAkap1 deficiency exacerbates diabetic cardiomyopathy by impeding mitochondrial translocation of NDUFS1 to induce mitochondrial dysfunction and cardiomyocyte apoptosis. Our findings suggest thatAkap1 upregulation has therapeutic potential for myocardial injury in individuals with diabetes.
Publication date: Available online 8 April 2020Source: JACC: Heart FailureAuthor(s): Sebhat Erqou, Lan Jiang, Gaurav Choudhary, Michelle Lally, Gerald S. Bloomfield, Andrew R. Zullo, Theresa I. Shireman, Mathew Freiberg, Amy C. Justice, James Rudolph, Nina Lin, Wen-Chih Wu
Publication date: Available online 8 April 2020Source: JACC: Heart FailureAuthor(s): Douglas L. Mann
Publication date: Available online 8 April 2020Source: JACC: Heart FailureAuthor(s): Sameer Prasada, Adovich Rivera, Arvind Nishtala, Anna E. Pawlowski, Arjun Sinha, Joshua D. Bundy, Simran A. Chadha, Faraz S. Ahmad, Sadiya S. Khan, Chad Achenbach, Frank J. Palella, Rosalind Ramsey-Goldman, Yvonne C. Lee, Jonathan I. Silverberg, Babafemi O. Taiwo, Sanjiv J. Shah, Donald M. Lloyd-Jones, Matthew J. Feinstein
Publication date: Available online 8 April 2020Source: JACC: Heart FailureAuthor(s): Mona Fiuzat, Naomi Lowy, Norman Stockbridge, Marco Sbolli, Federica Latta, JoAnn Lindenfeld, Eldrin F. Lewis, William T. Abraham, John Teerlink, Mary Walsh, Paul Heidenreich, Biykem Bozkurt, Randall C. Starling, Scott Solomon, G. Michael Felker, Javed Butler, Clyde Yancy, Lynne W. Stevenson, Christopher O'Connor, Ellis Unger
Publication date: Available online 8 April 2020Source: Canadian Journal of CardiologyAuthor(s): John L. Sapp, Wael Alqarawi, Ciorsti J. MacIntyre, Rafik Tadros, Christian Steinberg, Jason D. Roberts, Zachary Laksman, Jeff S. Healey, Andrew D. Krahn
Condition: Ischemic Cardiomyopathy Intervention: Device: Impella 5.0 Supported OPCABG Sponsor: Medical College of Wisconsin Not yet recruiting
Conclusions: The clinical course of patients with ICM and DCM treated with CRT-D differs significantly during long-term follow-up, with increased mortality and incidence of ICD therapies in ICM patients. PMID: 31360179 [PubMed]